3,370 reports of this reaction
3.1% of all ETONOGESTREL reports
#8 most reported adverse reaction
DEVICE DEPLOYMENT ISSUE is the #8 most commonly reported adverse reaction for ETONOGESTREL, manufactured by Organon LLC. There are 3,370 FDA adverse event reports linking ETONOGESTREL to DEVICE DEPLOYMENT ISSUE. This represents approximately 3.1% of all 110,074 adverse event reports for this drug.
Patients taking ETONOGESTREL who experience device deployment issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEVICE DEPLOYMENT ISSUE is moderately reported among ETONOGESTREL users, representing a notable but not dominant share of adverse events.
In addition to device deployment issue, the following adverse reactions have been reported for ETONOGESTREL:
The following drugs have also been linked to device deployment issue in FDA adverse event reports:
DEVICE DEPLOYMENT ISSUE has been reported as an adverse event in 3,370 FDA reports for ETONOGESTREL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEVICE DEPLOYMENT ISSUE accounts for approximately 3.1% of all adverse event reports for ETONOGESTREL, making it a notable side effect.
If you experience device deployment issue while taking ETONOGESTREL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.